Showing 4911-4920 of 5957 results for "".
- Iridex Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelineshttps://modernod.com/news/iridex-announces-micropulse-transscleral-laser-therapy-now-accepted-in-the-european-glaucoma-society-guidelines/2478696/Iridex reported that MicroPulse Transscleral Laser Therapy (TLT), which is performed using the Iridex Cyclo G6 Laser System and MicroPulse P3 Delivery Device, has been included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma. The EGS guidelines represent recommendat
- EU Authorizes First COVID-19 Vaccine With Pfizer, BioNTech’s Comirnatyhttps://modernod.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/The European Commission on Monday granted a conditional marketing authorization to Pfizer and BioNTech’s coronavirus vaccine BNT162b2, which will go by the name Comirnaty, with the decision coming mere hours after the Committee for Medicinal Products for Human Use (CHMP) gave its backing fo
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- EyeGate Pharma Announces Acquisition of Panoptes Pharmahttps://modernod.com/news/eyegate-pharma-announces-acquisition-of-panoptes-pharma/2478685/EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. EyeGate Pharmaceuticals will pay up to $4
- Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DMEhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-3-studies-for-dme/2478687/Genentech announced positive topline results from two identically designed global phase 3 studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a
- Vaccine Rollout On Track, Expect 300M Doses Through March: Fedshttps://modernod.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/If the initial success of the Pfizer-BioNTech rollout continues, and emergency use authorization (EAU) is granted to Moderna and Johnson & Johnson vaccines in development, Operation Warp Speed officials expect to have 300 million doses of COVID-19 vaccines to distribute across the United Stat
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- FDA Review Confirms Efficacy of Moderna’s mRNA-1273 Vaccine Against COVID-19https://modernod.com/news/fda-review-confirms-efficacy-of-modernas-mrna-1273-vaccine-against-covid-19/2478666/According to briefing documents released ahead of an FDA advisory panel meeting on December 17, agency staff concluded that the efficacy of Moderna’s candidate COVID-19 vaccine mRNA-1273 at preventing coronavirus infections 14 days after a second dose was consistent, at 94.1%, with results
- Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia/2478667/Eyenovia announced that the first set of patients has been enrolled in the company’s phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its Optejet dispenser, for the